Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
steroids
Pharma
FDA signs off on Santhera's muscular dystrophy drug Agamree
The FDA approval of Santhera’s Agamree to treat DMD is just a start. The company is anxious to see how many disorders the corticosteroid can treat.
Kevin Dunleavy
Oct 27, 2023 8:23am
Spiral winds up for sustained-release trial with $8M round
Jan 10, 2023 10:45am
Acasti plots path to phase 3 for steroid spray in rare disease
Jan 3, 2023 7:05am
Salvat heads to regulators with phase 3 data on ocular steroid
Apr 12, 2022 7:34am
MHRA flags risk of topical steroid withdrawal reactions
Sep 21, 2021 9:05am
Lyra data on steroid-eluting implant open up 505(b)(2) pathway
Jul 6, 2021 7:05am
